Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.99 - $2.68 $667,645 - $899,140
335,500 Added 1605.26%
356,400 $866,000
Q4 2022

Feb 14, 2023

SELL
$1.8 - $2.56 $164,282 - $233,646
-91,268 Reduced 81.37%
20,900 $39,000
Q3 2022

Feb 14, 2023

BUY
$1.94 - $3.43 $177,059 - $313,049
91,268 Added 436.69%
112,168 $269,000
Q3 2022

Nov 14, 2022

BUY
$1.94 - $3.43 $177,059 - $313,049
91,268 Added 436.69%
112,168 $269,000
Q1 2022

Feb 14, 2023

SELL
$1.95 - $3.89 $177,972 - $355,032
-91,268 Reduced 81.37%
20,900 $43,000
Q1 2022

May 13, 2022

SELL
$1.95 - $3.89 $105,885 - $211,227
-54,300 Reduced 72.21%
20,900 $44,000
Q4 2021

Feb 14, 2022

BUY
$3.81 - $6.16 $286,512 - $463,232
75,200 New
75,200 $296,000
Q3 2021

Nov 15, 2021

SELL
$3.38 - $5.35 $964,990 - $1.53 Million
-285,500 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$4.12 - $5.87 $481,216 - $685,616
-116,800 Reduced 29.03%
285,500 $1.31 Million
Q1 2021

May 14, 2021

BUY
$3.45 - $9.09 $1.17 Million - $3.09 Million
340,100 Added 546.78%
402,300 $2.36 Million
Q4 2020

Feb 12, 2021

BUY
$1.05 - $3.67 $65,310 - $228,274
62,200 New
62,200 $213,000
Q2 2020

Aug 14, 2020

SELL
$1.75 - $2.3 $33,775 - $44,390
-19,300 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$1.8 - $4.28 $207,723 - $493,920
-115,402 Reduced 85.67%
19,300 $38,000
Q4 2019

Feb 18, 2020

BUY
$3.16 - $5.15 $160,218 - $261,115
50,702 Added 60.36%
134,702 $559,000
Q3 2019

Nov 14, 2019

SELL
$1.2 - $6.66 $53,520 - $297,036
-44,600 Reduced 34.68%
84,000 $253,000
Q2 2019

Aug 13, 2019

BUY
$5.35 - $7.11 $385,200 - $511,920
72,000 Added 127.21%
128,600 $809,000
Q1 2019

May 14, 2019

BUY
$4.36 - $7.94 $246,776 - $449,404
56,600 New
56,600 $315,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $143M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.